Real‐World Overall Survival Comparison of Enzalutamide and Abiraterone In First‐ and Second‐Line Setting of Metastatic Castration‐Resistant Prostate Cancer
This health insurance-registry-based study suggests that, in the real-world mCRPC setting, enzalutamide is superior to abiraterone in terms of OS.
Authors
- Paweł Rajwa (ORCID: https://orcid.org/0000-0003-4073-6584)
- Ida Komka
- Célia Blasszauer
- Tamás Fazekas (ORCID: https://orcid.org/0000-0003-0068-4089)
- Péter Nyírády (ORCID: https://orcid.org/0000-0002-7037-4919)
- Tibor Szarvas (ORCID: https://orcid.org/0000-0002-6321-0799)
- Anikó Valikovics
- András Horváth (ORCID: https://orcid.org/0000-0002-1769-4892)
- Boris Hadaschik (ORCID: https://orcid.org/0000-0002-1052-2692)
- Dániel Reibl
- Áron Soós
Institutions
- Semmelweis University (HU)
- Comprehensive Cancer Center Vienna (AT)
- HUN-REN Veterinary Medical Research Institute (HU)
- Postgraduate School of Molecular Medicine (PL)
- University of Duisburg-Essen (DE)
- Medical University of Vienna (AT)
Publication Details
- Journal
- The Prostate
- Published
- 2025-06-08
- DOI
- https://doi.org/10.1002/pros.24923
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00